If you liked this article you might like

Teva Stock Gains, Leerink: Despite Patent Loss, No Generic Competition Until 2018
Mylan's EpiPen Assistance Program Could Hit Earnings
Why EpiPen, Why Now? Analysts Explain the Timing of Mylan's Trouble
Mylan Falls After Being Called Out on Price Increases -- Should You Worry?